Skip to content
CompletedEarly Phase 1

Drug Effects on Mood and Behavior - Expectancy

NCT07061886 · MESA-X · University of Chicago

Closed to entry
Status
Not accepting participants
Early Phase 1
Phase
42
Target enrolment
1
Study sites
1 US states

What it is testing

Summary

This study will examine the effects of a single low dose of the 5HT2A agonist LSD (Lysergic Acid Diethylamide) (13 µg) or placebo in individuals who are or are not explicitly told what drug they will receive. Although it is known that expectancies strongly influence subjective responses to most drugs, no studies have examined expectancies on response to a very low dose of LSD. This is especially important in the context of 'microdosing' of drugs. People who practice microdosing typically do so with strong expectations of positive effects, making it difficult to determine whether there is a pharmacological effect. To minimize expectancies in the laboratory, participants are usually not told exactly what drug they will receive (i.e., double-blind), but given a range of possibilities. In the present study, the study team will test half the subjects under single-blind conditions, where the participants (but not the research assistant) will know exactly what they are receiving. Other subjects will receive the usual instructions. Healthy volunteers will receive either a marginally detectable dose of LSD (13 micrograms) or placebo, under conditions where they i) know for sure what drug they are receiving or ii) where the identity of the drug is uncertain. Four groups of subjects (N=12 each) will attend single 4-hour laboratory session. The study team will examine subjective and behavioral responses to the drug in each of four conditions (Known-Drug; Known-Placebo; Uncertain-Drug; Uncertain-Placebo).

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Visual Analog Scale (VAS)

    Measured over During in-lab session: Pre-drug, and every 60 minutes post-drug from 0-4 hours

  • Addiction Research Center Inventory (ARCI)

    Measured over During in-lab session: Pre-drug, and every 60 minutes post-drug from 0-4 hours

  • Drug Effects Questionnaire (DEQ)

    Measured over During in-lab session: Pre-drug, and every 60 minutes post-drug from 0-4 hours

  • 5 Dimensions of Altered States of Consciousness (5D-ASC) scale

    Measured over End of session (4 hours post-drug)

  • Ultimatum Game

    Measured over During in lab session: 1.5 hours post-drug

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 40 Years
Ages
All
Sex
Accepted
Healthy volunteers
Inclusion Criteria: * English Fluency * High school education or higher * BMI between 19-30 kg/m2 Exclusion Criteria: * Individuals with a medical condition contraindicating study participation as determined by the study physician (e.g., liver disease, abnormal EKG, liver or cardiovascular disease) * High blood pressure (\>140/90) * Current suicidal ideation or suicide attempt in past 12 months * Past year severe substance use disorder * Personal or first-degree relative with history of psychosis * Currently taking any psychiatric medication (for conventional antidepressants must be off for ≥ 2 weeks) * Active panic disorder * Severe obsessive-compulsive disorder * Severe post-traumatic stress disorder * Women who are pregnant or planning to become pregnant

Where

1 study site

FacilityCityRegionCountry
University of ChicagoChicagoIllinoisUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT07061886 on ClinicalTrials.gov →

Last updated in the registry 2026-07-09. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits